Industry News


Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology

By Labmedica International staff writers
20 Jan 2022

Image: Ion Torrent Genexus System (Photo courtesy of Thermo Fisher Scientific)

Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.


The first-of-its-kind Genexus System is designed to be used in any lab and delivers comprehensive next-generation sequencing (NGS) results in as little as a single day – the same timeframe as single-gene tests, such as immunohistochemistry (IHC) assays. The Genexus system’s flexible batching makes it an attractive solution for hospital labs with low and medium testing volume by reducing the need to wait several days until a lab has a sufficient number of samples to test. The integrated purification system and sequencer enable sample preparation and processing with only 20 minutes of hands-on time and minimal user intervention, allowing for the democratization of NGS to community and regional cancer centers globally.


Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus on the Genexus System, paving the way toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic. As an IVD, the >500-gene assay will initially be able to provide physicians with information about patients’ tumors in accordance with established clinical evidence, applicable clinical trials, and future approval may assist with the selection of targeted therapies. Oncocyte will also develop its 27-gene expression DetermaIO test as a distributed kit on the Genexus. DetermaIO may predict response to immuno-oncology therapies based on data demonstrating potential pan-cancer utility and improvement over current standard-of-care tests.


“As many as 44% of newly diagnosed cancer patients may be eligible for immuno-oncology therapies, with additional patients potentially benefiting from other precision medicines, yet many patients’ tumors are never sequenced to determine if they may benefit from these targeted treatments,1” said Ron Andrews, President and Chief Executive Officer of Oncocyte. “In order to increase the number of patients benefiting from precision medicine, we need to expand the number of IVDs and develop these tests on instruments that are designed to make sequencing-based testing simple and more accessible. We have developed our Determa menu to ultimately become regulated kits for distribution ex-US on an IVD instrument. Our collaboration with Thermo Fisher using the Genexus System’s end-to-end automation enables that vision.”


“Leveraging Thermo Fisher’s proven global capabilities and installed base will enable us to expand the availability of IVD assays beyond the US. market. The collaboration with Thermo Fisher, along with the resulting IVD test kits and potential companion diagnostic tests that we will seek to develop and market together, will play a key role in helping us improve patient outcomes worldwide,” added Andrews.


“Genomic testing can have a dramatic impact on patient care, especially when results are available quickly to support early clinical decision-making,” said Garret Hampton, President, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “Today, access to comprehensive testing depends on where you are treated. Our goal is to democratize genomic profiling so it is available to patients right away in more clinical settings – ultimately, everywhere patients receive treatment. By partnering with Oncocyte to validate and co-develop new IVD assays, we are working to expand access to genomic profiling and spread the benefits of precision medicine to more patients.”


Related Links:
Thermo Fisher Scientific 
Oncocyte Corporation



E-mail Print
FaceBook Twitter Google+ Linked in

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrated systems for sequencing, flow cytometry and real-time, digital and end point PCR—from sample prep to data analysis. The company’s products and services help increase productivity and efficiency by providing rapid and accurate results for customers in the research, clinical and applied markets.
Gold member
More info

More articles about THERMO FISHER SCIENTIFIC

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
20 Jan 2021
Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD 450 million in cash.
Read More
05 Mar 2020
Thermo Fisher Scientific to Acquire QIAGEN N.V.
 Thermo Fisher Scientific Inc. (Waltham, MA, USA) has announced that it plans to acquire QIAGEN N.V. (Venlo, Netherlands), a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher's boards of directors and the managing board of QIAGEN have unanimously approved Thermo Fisher's proposal to acquire QIAGEN.
Read More
03 Oct 2017
Thermo LC-MS Solutions Receive ANVISA Registration in Brazil
Thermo Fisher Scientific’s liquid chromatography mass spectrometry (LC-MS) in vitro diagnostic (IVD) systems, which enable the quantitation of analytes in complex matrices, have received registration by Brazil’s National Health Surveillance Agency (ANVISA), allowing clinical laboratories in the country to now screen and quantify drugs efficiently.
Read More

Additional news

20 May 2022
Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business
QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.
Read More
16 May 2022
Medtronic Completes Acquisition of Intersect ENT to Add Innovative Sinus Implants to ENT Portfolio
Medtronic plc (Dublin, Ireland) has completed the acquisition of Intersect ENT (Menlo Park, CA, USA), thereby expanding the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.
Read More
12 May 2022
Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications
The global lateral flow assays market is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing prevalence of influenza, STDs, and tuberculosis worldwide and rising awareness among people about the availability of POCT kits.
Read More
11 May 2022
Global Rapid Test Kits Market Driven by Immunoassay and Chromatography-Based Tests
The global rapid test kits market size was valued at more than USD 25.50 billion in 2021 and is expected to register a CAGR of 8.1% over the 2019-2030 period to surpass USD 52 billion in 2030, driven primarily by the increasing prevalence of various infectious diseases.
Read More
03 May 2022
Meridian Acquires Euprotein to Further Expand Recombinant Protein Capabilities
Meridian Bioscience, Inc. (Cincinnati, OH, USA) has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. (North Brunswick Township, NJ, USA).
Read More
02 May 2022
Globe Scientific Acquired by L Squared Capital Partners
Globe Scientific (Mahwah, NJ, USA), a provider of laboratory consumable supplies, has been acquired by L Squared Capital Partners (Newport Beach, CA, USA), marking its third acquisition as part of GSI Group Holdings.
Read More
29 Apr 2022
GE Healthcare and Medtronic Collaborate to Improve Product Access for ASCs and OBLs
GE Healthcare (Chicago, IL, USA) and Medtronic (Doral, FL, USA) have entered into a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs) that will allow customers to access extensive product portfolios, financial solutions, and exceptional service.
Read More
22 Apr 2022
Global Diagnostic Imaging Market to Surpass USD 33 Billion by 2026
The global diagnostic imaging market is projected to grow at a CAGR of 4.9% from an estimated USD 27.5 billion in 2022 to over USD 33 billion by 2026, driven by technological advancements, favorable demographic factors in the developed regions, growing access to healthcare and rising income levels of the middle class population in the developing regions.
Read More
22 Apr 2022
Global Electrosurgery Market to Reach Almost USD 6 Billion by 2026
The global electrosurgery market is projected to grow at a CAGR of 3.6% from an estimated USD 5 billion in 2022 to almost USD 6 billion by 2026, driven by the rapidly rising number of surgeries being performed globally, an aging population, and increasing prevalence of various chronic diseases.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions